Evidence map›Paper›PMID 31932072›Full record

ArticleKidney international2020

Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.

Joshua A Walker, Sean Richards, Mostafa E Belghasem, Nkiruka Arinze, Sung Bok Yoo, Joseph Y Tashjian, Stephen A Whelan, Norman Lee, Vijaya B Kolachalama, Jean Francis and 3 more

Open access · greenAbstract read
In one paragraph

Article in Kidney international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Joshua A WalkerRenal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA; Whitaker Cardiovascular Institute, Boston University, Boston, Massachusetts, USA.
Sean RichardsRenal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
Mostafa E BelghasemDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
Nkiruka ArinzeRenal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
Sung Bok YooRenal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
Joseph Y TashjianRenal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
Stephen A WhelanDepartment of Chemistry, Boston University, Boston, Massachusetts, USA.
Norman LeeDepartment of Chemistry, Boston University, Boston, Massachusetts, USA.
Vijaya B KolachalamaWhitaker Cardiovascular Institute, Boston University, Boston, Massachusetts, USA.
Jean FrancisRenal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
Katya RavidWhitaker Cardiovascular Institute, Boston University, Boston, Massachusetts, USA.
David SherrDepartment of Environmental Health, Boston University School of Medicine, Boston, Massachusetts, USA.
Vipul C ChitaliaRenal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA; Veteran Affairs Boston Healthcare System, Boston, Massachusetts, USA; Global Co-Creation Labs, Institute of Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. Electronic address: vichital@bu.edu.
Boston University · USVA Boston Healthcare System · US

Funding

Training CoreP42ES007381 · NIEHS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SHERR, DAVID H · 1995 to 2019
$46.1M
Multidisciplinary Training in Cardiovascular ResearchT32HL007224 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HAMBURG, NAOMI MIRIAM, WAINFORD, RICHARD DAVID · 1985 to 2020
$12.3M
Mechanisms Regulating Megakaryocyte EndomitosisR01HL080442 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAVID, KATYA · 2006 to 2015
$3.6M
Impact of Biological, Clinical, and Social Determinants on Trauma and Trauma OutcomesT32GM086308 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Alik Farber, Daniel G. Remick · 2010 to 2026
$3.5M
A path to thrombosis in primary myelofibrosisR01HL136363 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAVID, KATYA · 2018 to 2021
$1.9M
Defining the Role of the AHR in Blood Cell SpecificationsR01ES025409 · NIEHS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MURPHY, GEORGE J, SHERR, DAVID H · 2016 to 2020
$1.8M
Role of c-Cbl in Colon cancerR01CA175382 · NCI · BOSTON MEDICAL CENTER · PI CHITALIA, VIPUL C · 2014 to 2018
$1.8M
Thrombotic complication of uremia: role of prothrombotic uremic solutesR01HL132325 · NHLBI · BOSTON MEDICAL CENTER · PI CHITALIA, VIPUL C · 2016 to 2019
$1.7M
NCI NIH HHS R01 CA175382NHLBI NIH HHS R01 HL080442NHLBI NIH HHS R01 HL132325NHLBI NIH HHS R01 HL136363NHLBI NIH HHS T32 HL007224NIEHS NIH HHS P42 ES007381NIEHS NIH HHS R01 ES025409NIGMS NIH HHS T32 GM086308
6 · The paper itself

Abstract

Emerging evidence in animal models of chronic kidney disease (CKD) implicates Aryl Hydrocarbon Receptor (AHR) signaling as a mediator of uremic toxicity. However, details about its tissue-specific and time-dependent activation in response to various renal pathologies remain poorly defined. Here, a comprehensive analysis of AHR induction was conducted in response to discrete models of kidney diseases using a transgenic mouse line expressing the AHR responsive-promoter tethered to a β-galactosidase reporter gene. Following validation using a canonical AHR ligand (a dioxin derivative), the transgenic mice were subjected to adenine-induced and ischemia/reperfusion-induced injury models representing CKD and acute kidney injury (AKI), respectively, in humans. Indoxyl sulfate was artificially increased in mice through the drinking water and by inhibiting its excretion into the urine. Adenine-fed mice showed a distinct and significant increase in β-galactosidase in the proximal and distal renal tubules, cardiac myocytes, hepatocytes, and microvasculature in the cerebral cortex. The pattern of β-galactosidase increase coincided with the changes in serum indoxyl sulfate levels. Machine-learning-based image quantification revealed positive correlations between indoxyl sulfate levels and β-galactosidase expression in various tissues. This pattern of β-galactosidase expression was recapitulated in the indoxyl sulfate-specific model. The ischemia/reperfusion injury model showed increase in β-galactosidase in renal tubules that persisted despite reduction in serum indoxyl sulfate and blood urea nitrogen levels. Thus, our results demonstrate a relationship between AHR activation in various tissues of mice with CKD or AKI and the levels of indoxyl sulfate. This study demonstrates the use of a reporter gene mouse to probe tissue-specific manifestations of uremia in translationally relevant animal models and provide hypothesis-generating insights into the mechanism of uremic toxicity that warrant further investigation.

Indexed as

Renal Insufficiency, ChronicUremiaAnimalsIndicanMiceMice, TransgenicReceptors, Aryl HydrocarbonIndicanReceptors, Aryl Hydrocarbonacute kidney injuryaryl hydrocarbonchronic kidney diseaseuremia

Identifiers

PMID31932072
PMCPMC9721455
OpenAlexW2982514595

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.